Data / Form D filings / 858 Therapeutics, Inc.
858 Therapeutics, Inc.: Form D filings
858 Therapeutics, Inc., a pharmaceuticals company in San Diego, CA, filed 3 Form D notices with the SEC between 2020 and 2024. The latest, on July 11, 2024, reports $25.2 million sold of a $50.4 million offering to 12 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3115 Merryfield Row, Suite 110, San Diego, CA, 92121
- Phone
- (858) 987-8380
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1806356
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 11, 2024 | New notice | $50,350,497 | $25,175,501 | $25,174,996 | 12 | Jun 26, 2024 | sec.gov |
| May 18, 2021 | New notice | $39,999,996 | $20,000,001 | $19,999,995 | 6 | May 4, 2021 | sec.gov |
| Mar 11, 2020 | New notice | $37,500,000 | $20,056,095 | $17,443,905 | 1 | Mar 3, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| James Veal | Executive Officer | |
| Jane Huang | Director | |
| Monal Mehta | Director | |
| Stafford Jeffrey | Executive Officer, Director | |
| Ali Behbahani | Director | |
| Katherine Bell-McGuinn | Executive Officer | |
| Clare Ozawa | Director |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Jul 8, 2024 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what 858 Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.